Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth

Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.

Report Highlights
The cytotoxic therapy cancer brands market is currently worth just over $10 billion and is forecast to grow to sales of almost $15 billion. The launch of the antimetabolite brands, Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitadine; Celgene) in the EU and Japanese markets contributes to this growth.

As a class, DNA-interactive cytotoxic therapy cancer brands contributed the highest proportion of sales in 2007 with $4.3 billion. This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to overtake.

Twenty four companies are involved in the development of currently approved cytotoxic therapy cancer brands, over half of which have more than one cytotoxic brand on the market. Sanofi-Aventis leads with four out of the 25 cytotoxic brands marketed, which made a collective $4,176m for the company in the seven major markets in 2007.
[Fade out the market survey infos]

Overview 1
Catalyst 1
Summary 1
Standard Chartered 5
Key findings 5
Company overview 5
Product overview 21
Company outlook 24
Datamonitor Competitor Benchmark 28
APPENDIX 31
Definitions 31
Supplementary data 31
Methodology 32
Further reading 33
Ask the analyst 34
Datamonitor consulting 34
Disclaimer 34
[Fade out table of contents]

S 250
Abbreviations 256
Report methodology 257
About Datamonitor 257
About Datamonitor Healthcare 257
Disclaimer 259
[Fade out list of tables / figures]